{"id":11417,"date":"2024-11-05T15:27:04","date_gmt":"2024-11-05T07:27:04","guid":{"rendered":"https:\/\/flcube.com\/?p=11417"},"modified":"2024-11-05T15:27:05","modified_gmt":"2024-11-05T07:27:05","slug":"windtree-therapeutics-secures-hong-kong-patent-for-istaroxime-heart-failure-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11417","title":{"rendered":"Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment"},"content":{"rendered":"\n

US biotechnology company Windtree Therapeutics, Inc. (NASDAQ: WINT<\/a>) has announced the receipt of a patent approval in Hong Kong for its drug istaroxime. The patent, titled \u201cIstaroxime-containing intravenous formulation for the treatment of heart failure (AHF),\u201d covers formulations comprising istaroxime and methods of use, either alone or in combination with other agents for the treatment and management of AHF. This patent, valid until 2039, complements the one granted in mainland China earlier this year (patent number ZL201980003356.1).<\/p>\n\n\n\n

History and Development of Istaroxime<\/strong>
Istaroxime, originally discovered by Italy-based Sigma-Tau (now Leadiant Biosciences), was sold to Taiwan\u2019s CVie Therapeutics in 2012. CVie later merged with Windtree in 2018. The molecule functions as a positive inotropic agent, increasing myocardial contractility through a dual mechanism: inhibiting Na+\/K+- ATPase while activating the SERCA2a calcium pump, which enhances calcium reuptake from the cytoplasm.<\/p>\n\n\n\n

Lee\u2019s Pharmaceutical Ltd’s Licensing Deal with Windtree<\/strong>
China-based Lee\u2019s Pharmaceutical Ltd (HKG: 0950<\/a>) invested USD 138 million to license the drug istaroxime and rostafuroxin from Windtree for Greater China in January this year, highlighting the drug’s potential impact on the regional market.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US biotechnology company Windtree Therapeutics, Inc. (NASDAQ: WINT) has announced the receipt of a patent…<\/p>\n","protected":false},"author":1,"featured_media":11418,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[69,941,165,1631,73,1632],"class_list":["post-11417","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cvd","tag-hkg-0950","tag-lees-pharmaceutical","tag-nasdaq-wint","tag-patents","tag-windtree-therapeutics"],"yoast_head":"\nWindtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US biotechnology company Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the receipt of a patent approval in Hong Kong for its drug istaroxime. The patent, titled \u201cIstaroxime-containing intravenous formulation for the treatment of heart failure (AHF),\u201d covers formulations comprising istaroxime and methods of use, either alone or in combination with other agents for the treatment and management of AHF. This patent, valid until 2039, complements the one granted in mainland China earlier this year (patent number ZL201980003356.1).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11417\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11417\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-05T07:27:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-05T07:27:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/fd05d2a69e371f54a182ea6d3a72f178.png\" \/>\n\t<meta property=\"og:image:width\" content=\"335\" \/>\n\t<meta property=\"og:image:height\" content=\"174\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11417#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11417\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment\",\"datePublished\":\"2024-11-05T07:27:04+00:00\",\"dateModified\":\"2024-11-05T07:27:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11417\"},\"wordCount\":196,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11417#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/fd05d2a69e371f54a182ea6d3a72f178.png\",\"keywords\":[\"CVD\",\"HKG: 0950\",\"Lee's Pharmaceutical\",\"NASDAQ: WINT\",\"Patents\",\"Windtree Therapeutics\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11417#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11417\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11417\",\"name\":\"Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11417#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11417#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/fd05d2a69e371f54a182ea6d3a72f178.png\",\"datePublished\":\"2024-11-05T07:27:04+00:00\",\"dateModified\":\"2024-11-05T07:27:05+00:00\",\"description\":\"US biotechnology company Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the receipt of a patent approval in Hong Kong for its drug istaroxime. The patent, titled \u201cIstaroxime-containing intravenous formulation for the treatment of heart failure (AHF),\u201d covers formulations comprising istaroxime and methods of use, either alone or in combination with other agents for the treatment and management of AHF. This patent, valid until 2039, complements the one granted in mainland China earlier this year (patent number ZL201980003356.1).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11417#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11417\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11417#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/fd05d2a69e371f54a182ea6d3a72f178.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/fd05d2a69e371f54a182ea6d3a72f178.png\",\"width\":335,\"height\":174,\"caption\":\"Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11417#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment - Insight, China's Pharmaceutical Industry","description":"US biotechnology company Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the receipt of a patent approval in Hong Kong for its drug istaroxime. The patent, titled \u201cIstaroxime-containing intravenous formulation for the treatment of heart failure (AHF),\u201d covers formulations comprising istaroxime and methods of use, either alone or in combination with other agents for the treatment and management of AHF. This patent, valid until 2039, complements the one granted in mainland China earlier this year (patent number ZL201980003356.1).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11417","og_locale":"en_US","og_type":"article","og_title":"Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11417","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-05T07:27:04+00:00","article_modified_time":"2024-11-05T07:27:05+00:00","og_image":[{"width":335,"height":174,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/fd05d2a69e371f54a182ea6d3a72f178.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11417#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11417"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment","datePublished":"2024-11-05T07:27:04+00:00","dateModified":"2024-11-05T07:27:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11417"},"wordCount":196,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=11417#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/fd05d2a69e371f54a182ea6d3a72f178.png","keywords":["CVD","HKG: 0950","Lee's Pharmaceutical","NASDAQ: WINT","Patents","Windtree Therapeutics"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11417#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11417","url":"https:\/\/flcube.com\/?p=11417","name":"Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=11417#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=11417#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/fd05d2a69e371f54a182ea6d3a72f178.png","datePublished":"2024-11-05T07:27:04+00:00","dateModified":"2024-11-05T07:27:05+00:00","description":"US biotechnology company Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the receipt of a patent approval in Hong Kong for its drug istaroxime. The patent, titled \u201cIstaroxime-containing intravenous formulation for the treatment of heart failure (AHF),\u201d covers formulations comprising istaroxime and methods of use, either alone or in combination with other agents for the treatment and management of AHF. This patent, valid until 2039, complements the one granted in mainland China earlier this year (patent number ZL201980003356.1).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11417#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11417"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=11417#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/fd05d2a69e371f54a182ea6d3a72f178.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/fd05d2a69e371f54a182ea6d3a72f178.png","width":335,"height":174,"caption":"Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11417#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/fd05d2a69e371f54a182ea6d3a72f178.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11417"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11417\/revisions"}],"predecessor-version":[{"id":11420,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11417\/revisions\/11420"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/11418"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}